

1. (Previously Presented) An orally disintegrable tablet which comprises
- (i) fine granules having an average particle diameter of 400  $\mu\text{m}$  or less,  
which fine granules comprise a composition coated by an enteric  
coating layer comprising a first component which is an enteric coating  
agent and a second component which is a sustained release agent, said  
composition having 10 weight % or more of an acid-labile  
physiologically active substance and
- (ii) an additive  
wherein said tablet having a hardness strength of about 1 to about 20 kg is orally  
disintegrable;  
and wherein the oral disintegration time of said tablet is one minute or less.
2. (Original) An orally disintegrable tablet of claim 1, wherein the average particle  
diameter of the fine granules is 300 to 400  $\mu\text{m}$ .
3. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules further  
comprise a basic inorganic salt.
4. (Original) An orally disintegrable tablet of claim 1, wherein the additive  
comprises a water-soluble sugar alcohol.
5. (Original) An orally disintegrable tablet of claim 1, wherein the composition coated  
by an enteric coating layer is further coated by a coating layer which comprises a  
water-soluble sugar alcohol.

6. (Original) An orally disintegrable tablet of claim 4, wherein the additive comprises  
(i) crystalline cellulose and/or (ii) low-substituted hydroxypropyl cellulose.

7. (Original) An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 425 µm or less.

8. (Cancelled)

9. (Original) An orally disintegrable tablet of claim 1, wherein the acid-labile physiologically active substance is a benzimidazole compound or a salt thereof.

*11*  
*cont.*  
10. (Cancelled)

11. (Original) An orally disintegrable tablet of claim 3, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.

12. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.

13. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 50 weight % or more of lactose.

14. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.

15. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 weight % or more of an acid-labile physiologically active substance.

16. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.

17. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.

*cont.*

18. (Original) An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.

19. (Original) An orally disintegrable tablet of claim 18, wherein the aqueous enteric polymer agent is a methacrylate copolymer.

20. (Cancelled)

21. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.

22. (Previously Presented) An orally disintegrable tablet of claim 1, wherein

the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.

23. (Original) An orally disintegrable tablet of claim 4, wherein the water-soluble sugar alcohol is erythritol.

24. (Original) An orally disintegrable tablet of claim 4, wherein the water-soluble sugar alcohol is mannitol.

25. (Original) An orally disintegrable tablet of claim 5, wherein the water-soluble sugar alcohol is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules.

*Original*

26. (Original) An orally disintegrable tablet of claim 4, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.

27. (Original) An orally disintegrable tablet of claim 6, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 7.0 to 9.9 weight %.

28. (Original) An orally disintegrable tablet of claim 6, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 5.0 to 7.0 weight %.

29. (Original) An orally disintegrable tablet of claim 1, which further comprises crospovidone.

30. (Cancelled)

*31. (Original)* 31. (Original) An orally disintegrable tablet of claim 1, which comprises no lubricant inside  
the tablet.

Claims 32-49. (Cancelled)

---